Liver Cirrhosis clinical trials
The registry lists 1,300 studies for Liver Cirrhosis across more than 10 countries. 341 are recruiting or about to start. 790 of them are mainly about Liver Cirrhosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 2 narrower conditions too, such as Liver Cirrhosis, Biliary: 1,543 studies, 398 open.
ClinicalTrials.gov finds 2,739 studies for Liver Cirrhosis. How that becomes 1,296 here
This page counts the studies the registry files under Liver Cirrhosis, and those it files under no condition that list Liver Cirrhosisthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count
- 2,739Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
- −242Filed under a narrower condition, counted on its own pageLiver Cirrhosis, Biliary 204 · Liver Cirrhosis, Alcoholic 38
- −11List Liver Cirrhosis as a condition, but the registry did not file them under itMost often written as “Liver Cirrhosis, Experimental” (2), “Sarcopenia in Liver Cirrhosis” (2), and “Liver Cirrhosis Due to Virus C Chronic Hepatitis” (1). The registry filed them under other conditions only, most often Fibrosis (6) and Sarcopenia (3).
- −1,190Match it another way130 name it in the title, 5 in a keyword, and 1,055 by a synonym or other text the search reads.
- 1,296The count on this page29 of them list Liver Cirrhosis in their own words; the registry filed them under no condition.
Get an email when these change. Save the Liver Cirrhosis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Institute of Liver and Biliary Sciences, India (53) · Assiut University (35) · Post Graduate Institute of Medical Education and Research, Chandigarh (17) · Beijing Friendship Hospital (16) · Air Force Military Medical University, China (16) · Assistance Publique - Hôpitaux de Paris (16) · Seoul National University Hospital (15) · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (11)
What is being tested here
Drugs under test in Liver Cirrhosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Albumins | 3 | 0 | 6 |
| Apixaban | 3 | 1 | 3 |
| Simvastatin | 2 | 2 | 8 |
| Hydronidone | 2 | 3 | 6 |
| Solizmestrocel | 2 | 0 | 4 |
| Rifaximin | 1 | 6 | 18 |
| AZD2389 | 1 | 0 | 6 |
| Probiotic | 1 | 0 | 5 |
| Terlipressin | 1 | 1 | 5 |
| ICG 001 | 1 | 0 | 4 |
Drug classes tested here Statins 4 open · Proton pump inhibitors (PPIs) 3 open · Factor Xa inhibitors 3 open · Tyrosine kinase inhibitors (TKIs) 2 open · SGLT2 inhibitors 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Dec 2026A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) · Phase 3 · Madrigal Pharmaceuticals, Inc.
- Mar 2027Efficacy of Simvastatin in Alcoholic Liver Fibrosis · Phase 3 · Anna Cruceta
- Nov 2026Equivalence of Electronic vs Paper-based PHES in Diagnosing Hepatic Encephalopathy · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Nov 2026Ketogenic Diet in MASLD-related cACLD · University of Palermo
- Nov 2026A Clinical Cohort Study on the Pathogen Spectrum of Hepatic Virus-caused Cirrhosis Complicated With Infection · Zhejiang University
- Nov 2026Evaluation of the Efficacy and Safety of Portal Pressure Gradient (PPG) Measurement Guided by Endoscopic Ultrasound (EUS) in the Therapeutic Algorithm of Patients with Liver Cirrhosis. · Hospital Universitario Virgen Macarena
- Nov 2026The Liver Care Trial · Zealand University Hospital
- Nov 2026Verification of Risk Factors of Thrombohemorrhagic Complications in Recipients After Related Liver Transplantation · Republican Specialized Scientific and Practical Medical Center of Surgery Named After V. Vakhidov
- Nov 2026Ursodeoxycholic Acid in Patients With NAFLD - Clinical Observation · General University Hospital, Prague
- Dec 2026Angiotensin 2 for AKI After OLT · University of California, Los Angeles
Who these studies take
Of the 209 Liver Cirrhosis studies recruiting now, 101 (48%) set no upper age limit and 67 (32%) stop at 75 or younger. 12 (6%) take children under 18. 1 (<1%) are for women only and 1 (<1%) for men only; 25 (12%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 10 (5%) | 10 (5%) |
| 18 | 189 (90%) | 189 (90%) |
| 30 | 199 (95%) | 199 (95%) |
| 40 | 200 (96%) | 200 (96%) |
| 50 | 203 (97%) | 203 (97%) |
| 65 | 200 (96%) | 200 (96%) |
| 75 | 174 (83%) | 174 (83%) |
| 85 | 120 (57%) | 119 (57%) |
Across all 1,300 studies, recruiting or not: 42% stop at 75 or younger and 16% at 65; 10% take children; <1% are for women only and 1% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Liver Cirrhosis studies take
Of 55 phase 2 interventional studies under Liver Cirrhosis, half reached primary completion within 27 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 15 mo2–29 · 32 studies | — | — |
| Phase 2 | 27 mo19–56 · 55 studies | 24 mo16–27 · 28 studies | — |
| Phase 3 | 66 mo25–82 · 25 studies | — | — |
| Phase 4 | 42 mo13–… · 36 studies | — | — |
| Interventional, no phase | 32 mo17–54 · 215 studies | — | 36 mo19–73 · 206 studies |
| Observational | 47 mo18–71 · 247 studies | — | 47 mo18–71 · 231 studies |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 14, 2026.
Started recruiting4
- Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF)Nov 12, 2026NCT04939441
- Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Nov 2, 2026NCT07854782
- Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)Oct 26, 2026NCT07631637
- Elastography-based Brief Alcohol Intervention in Hospitalized IndividualsOct 22, 2026NCT07637539
Results posted2
Stopped2
- Evaluation of Accuvein in Cirrhotics PatientsTerminatedNov 12, 2026NCT03996135
- Low-Dose Danazol for the Treatment of Telomere Related DiseasesTerminatedOct 27, 2026NCT03312400
Newly registered12
- Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD)Nov 12, 2026NCT07933328
- Prospective AI-SC TrialNov 10, 2026NCT07927153
- Liver Fibrosis Risk With Methotrexate ExposureNov 10, 2026NCT07928921
- The Value of Spleen Thickness and Spleen Diameter for Gastroesophageal Varices Diagnosis in Compensated CirrhosisNov 6, 2026NCT07920744
- Optimal Treatment Strategy for Spontaneous Bacterial PeritonitisNov 6, 2026NCT07923318
Show 7 moreShow fewer
- Prickly Pear Pulp Powder Along With an Anti-inflammatory Diet in Patients Having Liver FibrosisOct 29, 2026NCT07903103
- Effect of Mini-Program Monitoring on Hepatic Encephalopathy in Post-TIPS PatientsOct 28, 2026NCT07901556
- AI-SC Multi-center StudyOct 21, 2026NCT07885007
- Safety of Anticoagulation Therapy in Cirrhotic Patients With PVT and Severe ThrombocytopeniaOct 21, 2026NCT07885969
- Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLDOct 16, 2026NCT07877272
- Within-Session Repeatability of EUS-Guided Portal Pressure Gradient MeasurementOct 16, 2026NCT07877298
- Equivalence of Electronic vs Paper-based PHES in Diagnosing Hepatic EncephalopathyOct 14, 2026NCT07874204
Studies
Recruiting first, then most recently updated. Showing 50 of 1,300. Browse all 1,300 → or search them.
- Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF)RecruitingNCT04939441Phase 41 country
- A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)RecruitingNCT07325526Phase 22 countries
- Artificial Intelligence-Assisted Care After Hospital Discharge for People With Decompensated CirrhosisNot yet recruitingNCT07931404Not applicable1 country
- Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in EuropeRecruitingNCT0758589010 countries
- Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD)Not yet recruitingNCT07933328Phase 2
- Isocaloric Navy-Bean Substitution in Adults With MASLDNot yet recruitingNCT07730853Not applicable1 country
- Endoscopic Ultrasound Shear Wave Elastography StudyRecruitingNCT065928201 country
- Prospective AI-SC TrialNot yet recruitingNCT079271531 country
- Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)RecruitingNCT07631637Phase 23 countries
- The Value of Spleen Thickness and Spleen Diameter for Gastroesophageal Varices Diagnosis in Compensated CirrhosisRecruitingNCT079207441 country
- Optimal Treatment Strategy for Spontaneous Bacterial PeritonitisRecruitingNCT07923318Not applicable1 country
- Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)RecruitingNCT07854782Phase 31 country
- High Dose Albumin in Refractory AscitesRecruitingNCT05867602Phase 21 country
- Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced FibrosisRecruitingNCT07610837Phase 22 countries
- Prickly Pear Pulp Powder Along With an Anti-inflammatory Diet in Patients Having Liver FibrosisNot yet recruitingNCT07903103Not applicable1 country
- LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisRecruitingNCT06632444Phase 337 countries
- Effect of Mini-Program Monitoring on Hepatic Encephalopathy in Post-TIPS PatientsNot yet recruitingNCT07901556Not applicable
- Evaluation of Non-Invasive Tests for Metabolic Liver DiseaseRecruitingNCT071227001 country
- Within-Session Repeatability of EUS-Guided Portal Pressure Gradient MeasurementNot yet recruitingNCT078772984 countries
- Elastography-based Brief Alcohol Intervention in Hospitalized IndividualsRecruitingNCT07637539Not applicable1 country
- Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft TissuesRecruitingNCT017577301 country
- Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLDRecruitingNCT078772721 country
- Daridorexant for Sleep Disturbance in Adults With Liver CirrhosisNot yet recruitingNCT07830303Phase 41 country
- Equivalence of Electronic vs Paper-based PHES in Diagnosing Hepatic EncephalopathyNot yet recruitingNCT07874204Not applicable
- Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver CirrhosisRecruitingNCT062652721 country
- Periinterventional Coagulation Management of Patients Undergoing a TIPSRecruitingNCT04421924Not applicable1 country
- Microbiome and Sarcopenia in Patients With Liver CirrhosisRecruitingNCT03080129Not applicable1 country
- HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver DiseaseRecruitingNCT05205954Not applicable1 country
- Safety and Efficacy of Atorvastatin v. Placebo on HCC RiskRecruitingNCT05028829Phase 21 country
- Lifestyle, Dietary Patterns, and Cardiometabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease Among People Living With HIVNot yet recruitingNCT07861594
- A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With HemophiliaRecruitingNCT07681089Phase 21 country
- Electronic PHES vs Paper-based PHES for Hepatic EncephalopathyNot yet recruitingNCT07852416Not applicable1 country
- A Prospective Cohort Study on the Epidemiological Investigation, Diagnosis, and Treatment of Hepatic EncephalopathyNot yet recruitingNCT076126701 country
- Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United StatesRecruitingNCT05832229Phase 21 country
- Molecular Mechanism of Exercise in CirrhosisRecruitingNCT05982769Not applicable1 country
- HMB Enriched Amino Acids to Reverse Muscle Loss in CirrhosisRecruitingNCT05166499Not applicable1 country
- National Liver Cancer Screening TrialRecruitingNCT06084234Phase 41 country
- Nutritional Indices and Inflammatory Markers in MASLDNot yet recruitingNCT07834905
- A Novel Extracorporeal Liver Support Therapy In ALCF and to Evaluate the Efficacy of DIALIVE 2.0, a Liver Dialysis Device.RecruitingNCT07347275Not applicable1 country
- Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic CirrhosisRecruitingNCT04689152Phase 31 country
- Impact of Overt and Subclinical Hypothyroidism on Liver Fibrosis in Patients With MASLDNot yet recruitingNCT07827430
- Effect of Handgrip Strength on Portal Vein Hemodynamics in Patients With Liver CirrhosisRecruitingNCT07116096Not applicable1 country
- Using Autologous Bone Marrow Cells With Wharton Gel Exosomes to Stimulate Hepatic Cell Repair in Liver CirrhosisRecruitingNCT07374185Not applicable1 country
- A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial).RecruitingNCT05895136Phase 25 countries
- Effect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune FunctionRecruitingNCT078116871 country
- Umbilical Cord Mesenchymal Stem Cell Therapy for Biliary AtresiaRecruitingNCT07797673Phase 11 country
- Coil-Assisted Small-Diameter Covered-Stent Shunt Reduction for Refractory Hepatic Encephalopathy After TIPSRecruitingNCT07799948Not applicable1 country
- Hypothyroidism and Liver Fibrosis Severity in MASLDNot yet recruitingNCT07793279
- Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Variceal Bleeding and Renal DysfunctionNot yet recruitingNCT07252401Not applicable1 country
- Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in CirrhosisRecruitingNCT03208868Not applicable1 country